Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial.

Ueki, Yasushi; D Häner, Jonas; Losdat, Sylvain; Gargiulo, Giuseppe; Shibutani, Hiroki; Bär, Sarah; Otsuka, Tatsuhiko; Kavaliauskaite, Raminta; R Mitter, Vera; Temperli, Fabrice; Spirk, David; Stortecky, Stefan; C M Siontis, George; Valgimigli, Marco; Windecker, Stephan; Gutmann, Clemens; C Koskinas, Konstantinos; Mayr, Manuel; Räber, Lorenz

doi:10.1055/a-2156-7872

Public

Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial.

Shared by NobleBlocks on Jun 1, 2024 • 12:00 AM UTC

Authors:

Yasushi Ueki

Jonas D Häner

Sylvain Losdat

Abstract

OBJECTIVE: The effect of the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor alirocumab on platelet aggregation among patients with acute myocardial infarction (AMI) remains unknown. We aimed to explore the effect of alirocumab added to high-intensity statin therapy on P2Y12 reaction...

Discussions